Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab for CRS Prophylaxis in Teclistamab/Talquetamab Therapy for Relapsed/Refractory Myeloma
NCT07657312Phase 2Recruiting
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of infliximab in cytokine release syndrome (CRS). Primary endpoint: Incidence of all-grade cytokine release syndrome (CRS) at 28 days. Started Jul 2026; status: recruiting.
02
Drugs
infliximab
03
Conditions
cytokine release syndrome (CRS)
Beyond the preview
Go deeper on NCT07657312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07657312.